| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Ardelyx, Inc. (ARDX) has 9 insiders with recent SEC Form 4 filings, including 0 buys and 11 sells. ARDX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 3.30M | $21.04M | - | |
| CEO | 1.74M | $11.09M | -41,666 | |
| Other | 409.9K | $2.61M | - | |
| CFO | 409.1K | $2.61M | - | |
| Other | 339.5K | $2.16M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 4, 2019 | Grammer Elizabeth A58 | SVP, General Counsel | Sell | 2,520 | $2.54 | $6,404.08 | -1.9% | |
| Jun 4, 2019 | Rosenbaum David P.59 | Chief Development Officer | Sell | 2,856 | $2.54 | $7,258.24 | -1.8% | |
| Jun 4, 2019 | Raab Michael56 | President &CEO | Sell | 10,054 | $2.54 | $25,551.24 | -3.8% | |
| Jan 2, 2019 | Kaufmann Mark | Chief Financial Officer | Sell | 6,556 | $1.70 | $11,154.38 | -4.5% | |
| Jan 2, 2019 | Rosenbaum David P.59 | Chief Development Officer | Sell | 6,386 | $1.70 | $10,865.78 | -3.5% | |
| Jan 2, 2019 | Raab Michael56 | President &CEO | Sell | 19,644 | $1.70 | $33,418.37 | -7.0% | |
| Jan 2, 2019 | Grammer Elizabeth A58 | EVP, General Counsel | Sell | 4,920 | $1.70 | $8,369.90 | -3.7% | |
| Nov 13, 2018 | Kaufmann Mark | Chief Financial Officer | Sell | 6,539 | $2.84 | $18,570.76 | -4.3% | |
| Nov 13, 2018 | Grammer Elizabeth A58 | EVP, General Counsel | Sell | 6,539 | $2.84 | $18,570.76 | -4.6% | |
| Nov 13, 2018 | Raab Michael56 | President &CEO | Sell | 6,539 | $2.84 | $18,570.76 | -2.2% |